Biotech
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Discovery Labs Holds Out Hope for Surfaxin
- Feuerstein's Biotech-Stock Mailbag
- FDA Approval Delay Sinks Discovery Labs
- Del.icio.us
- Digg
- StumbleUpon
Onyx Pharmaceuticals ONXX posted a first-quarter profit and beat Wall Street expectations Tuesday, boosted by sales of its anti-cancer drug Nexavar. The Emeryville, Calif.-based company after the market close reported earnings of $15.4 million, or 27 cents a share, vs. a loss of $12.2 million, or 26 cents a share, a year earlier. Bayer BAYRY.PK, Onyx's partner for kidney and liver cancer treatment Nexavar, reported sales of $151.9 million from the drug, compared to $60.9 million a year earlier. Based on that, Onyx reported net revenue from unconsolidated joint business of $37.7 million, compared to $3 million a year earlier. The results beat by far what analysts, according to the Thomson Financial consensus target, were expecting: a loss of 6 cents a share on revenue of $11.7 million. On the expense side, R&D spending increased roughly 35% to $7.4 million, due to higher costs in the company's breast cancer program. Selling, general and administrative expenses increased 51% to $19.8 million, primarily due to an increase in stock-based compensation, other employee-related expenses and marketing expenses. Shares were up 56 cents, or 1.5%, at $38.50 in recent post-market trading Tuesday.
The stock Monday regains some of its sharp Friday losses on the company's positive response to FDA delays. But is the reaction overly optimistic?
Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.
Surfaxin receives an approvable letter, but the additional delays that accompany it send shares plummeting in premarket trading.
Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Ensco International and Echelon have the potential to move higher in coming days.
See who made what calls.
The addition of video is helping telecom companies compete against cable and satellite companies.
The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.
See who made what calls.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
Sponsored by:
RSS
